The effect of choline-stabilized orthosilicic acid in patients with peri-implantitis: an exploratory randomized, double-blind, placebo controlled study

The effect of choline-stabilized orthosilicic acid in patients with peri-implantitis: an exploratory randomized, double-blind, placebo controlled study

Abstract Background Choline-stabilized orthosilicic acid (CS-OSA) was previously found to stimulate bone collagen formation in osteopenia and to improve biomarkers of cartilage degradation in knee osteoarthritis. The aim of the present study was to investigate the effect of oral administration of CS...

Full description

Saved in:
Bibliographic Details
Published in:BMC oral health Vol. 21; no. 1; pp. 1 - 485
Main Authors: Teughels, Wim, Celik, Gizem Unal, Tarce, Mihai, De Cock, Ine, Persyn, Sara M, Haytac, Mehmet C
Format: Journal Article
Language:English
Published: London BioMed Central Ltd 29-09-2021
BioMed Central
BMC
Subjects:
Acids
Analysis
Antibiotics
Bone
Bone density
Bone growth
Bone healing
Bone loss
Bone surgery
Cartilage
Cartilage diseases
Choline
Choline-stabilized orthosilicic acid
Clinical trials
Collagen
Complications and side effects
Computed tomography
Dental implants
Dentistry
Dietary supplements
Double-blind studies
Drug therapy
Implant dentures
Inflammation
Metabolism
Mucosa
Mucosal recession
Oral administration
Oral hygiene
Oral medication
Osteoarthritis
Osteopenia
Patient outcomes
Patients
Peri-implantitis
Placebos
Questionnaires
Shoulder
Substance abuse treatment
Surgery
Testing
Womens health
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Choline-stabilized orthosilicic acid (CS-OSA) was previously found to stimulate bone collagen formation in osteopenia and to improve biomarkers of cartilage degradation in knee osteoarthritis. The aim of the present study was to investigate the effect of oral administration of CS-OSA on clinical symptoms of peri-implantitis and the associated bone loss. Methods Twenty-one patients with peri-implantitis were randomized in CS-OSA or placebo groups. After initial clinical and cone beam computed tomography (CBCT) measurements [probing pocket depth (PPD), bleeding on probing (BOP), mucosal recession (REC), distance from implant shoulder to alveolar crest (IS-AC) and distance from implant shoulder to first bone-to-implant contact (IS-BIC)], flap operations were performed at the peri-implantitis sites. All patients were instructed to use either placebo or CS-OSA capsules twice a day for 1 year. Measurements were repeated 6 and 12 months after randomization. Results The data of 18 patients (36 implants) were used in the per protocol analysis. PPD and BOP improved significantly ( p  < 0.05) compared to baseline for both groups after 6 and 12 months. However, REC significantly increased in the placebo group but not in the CS-OSA group. The change in REC over 6 and 12 months was significantly different between groups ( p  < 0.01). IS-BIC and IS-AC measurements remained stable in the CS-OSA group whereas in the placebo group, both parameters increased significantly after 6 and 12 months. The change in IS-BIC over 12 months was significantly different between groups (p < 0.05). Conclusion The results of this preliminary study suggest that CS-OSA may stabilize and even prevent further bone loss after surgical peri-implantitis treatment and support mucosal tissue healing. Trial registration The trial was retrospectively registered at ISRCTN registry, registration number: ISRCTN14348802, registration date: 24/06/2020.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:1472-6831
1472-6831
DOI:10.1186/s12903-021-01817-4